CAS NO: | 1075236-89-3 |
生物活性 | Gepotidacin (GSK2140944) is a novel triazaacenaphthylenebacterialtype IItopoisomeraseinhibitor. | ||||||||||||||||
体外研究 (In Vitro) | Gepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism and has demonstratedin vitroactivity against gram-negative and gram-positive bacterias , including drug-resistant strains, and also targets pathogens associated with other conventional and biothreat infections. The MIC50and MIC90for gepotidacin against the 25N. gonorrhoeaeisolates tested are 0.12 and 0.25 μg/mL, respectively[1]. The gepotidacin MIC90s are as follows (in μg/mL):Streptococcus pyogenes, 0.25;Escherichia coli, 2;Moraxella catarrhalis, ≤0.06;Streptococcus pneumoniae, 0.25;Haemophilus influenzae, 1;Clostridium perfringens, 0.5; andShigella spp., 1[2]. Gepotidacin hasin vitroactivity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs)[3]. | ||||||||||||||||
体内研究 (In Vivo) | GSK2140944 MICs are 0.125 to 0.5 mg/L against the six MRSA isolates. ELF penetration ratios range from 1.1 to 1.4. Observed maximal decreases are 1.1 to 3.1 log10 CFU in neutropenic mice. The mean fAUC/MIC ratios required for stasis and 1-log-unit decreases are 59.3 ± 34.6 and 148.4 ± 83.3, respectively. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 448.52 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H28N6O3 | ||||||||||||||||
CAS 号 | 1075236-89-3 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 7.14 mg/mL(15.92 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |